Vertex Pharmaceuticals Incorporated  

(Public, NASDAQ:VRTX)   Watch this stock  
Find more results for Joshua I. Smith
+1.92 (1.81%)
After Hours: 108.09 0.00 (0.00%)
Oct 23, 5:14PM EDT  
NASDAQ real-time data - Disclaimer
Currency in USD
Range 106.33 - 109.55
52 week 58.06 - 116.88
Open 107.03
Vol / Avg. 0.00/2.07M
Mkt cap 25.28B
P/E     -
Div/yield     -
EPS -2.03
Shares 238.08M
Beta 0.44
Inst. own 92%
Oct 28, 2014
Q3 2014 Vertex Pharmaceuticals Inc Earnings Call - 5:00PM EDT - Add to calendar
Oct 28, 2014
Q3 2014 Vertex Pharmaceuticals Inc Earnings Release - 4:00PM EDT - Add to calendar
Oct 10, 2014
Vertex Pharmaceuticals Inc NACF Investor Event
Sep 23, 2014
Vertex Pharmaceuticals Inc at EBD Group BioPharm America
Sep 10, 2014
Vertex Pharmaceuticals Inc at Morgan Stanley Healthcare Conference
Jul 29, 2014
Q2 2014 Vertex Pharmaceuticals Inc Earnings Call - Webcast
Jul 29, 2014
Q2 2014 Vertex Pharmaceuticals Incorporated Earnings Release
More events from DailyFinance »    

Key stats and ratios

Q2 (Jun '14) 2013
Net profit margin -115.14% -56.73%
Operating margin -104.13% -74.54%
EBITD margin - 6.49%
Return on average assets -29.63% -27.08%
Return on average equity -53.20% -37.78%
Employees 1,800 -
CDP Score - -


50 Northern Avenue
BOSTON, MA 02210
United States - Map
+1-617-3416393 (Phone)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


Vertex Pharmaceuticals Incorporated (Vertex) is in the business of discovering, developing, manufacturing and commercializing small molecule drugs for the treatment of serious diseases. The Company�s two products are INCIVEK (telaprevir), which is approved for the treatment of patients with genotype 1 hepatitis C virus (HCV), infection, and KALYDECO (ivacaftor), which is approved in the United States for the treatment of patients six years of age and older with cystic fibrosis (CF), who have at least one copy of the G551D mutation in the cystic fibrosis transmembrane conductance regulator (CFTR), gene. The Company has ongoing clinical programs involving drug candidates intended for the treatment of HCV infection, CF, rheumatoid arthritis, influenza and epilepsy. INCIVEK (telaprevir) achieved initial commercial acceptance following its approval in May 2011. It started marketing KALYDECO in the United States in January 2012.

Officers and directors

Jeffrey M. Leiden M.D., Ph.D. Chairman of the Board, President, Chief Executive Officer
Bio & Compensation  - Reuters
Ian F. Smith CPA Chief Financial Officer, Executive Vice President
Age: 48
Bio & Compensation  - Reuters
Peter Mueller Ph.D. Executive Vice President - Global Research and Development, Chief Scientific Officer
Age: 57
Bio & Compensation  - Reuters
Stuart A. Arbuckle Executive Vice President, Chief Commercial Officer
Age: 48
Bio & Compensation  - Reuters
Jeffrey A. Chodakewitz M.D. Chief Medical Officer and Senior Vice President - Global Medicines Development
Bio & Compensation  - Reuters
Kenneth L. Horton Executive Vice President, Chief Legal Officer
Age: 47
Bio & Compensation  - Reuters
Paul M. Silva Senior Vice President, Corporate Controller
Age: 48
Bio & Compensation  - Reuters
Thomas F. Connolly Senior Vice President, Director of Human Resources
Age: 56
Bio & Compensation  - Reuters
Megan Pace Senior Vice President - Corporate Communications
Age: 41
Bio & Compensation  - Reuters
Amit K. Sachdev J.D. Senior Vice President - Global Government Strategy, Market Access and Value
Age: 46
Bio & Compensation  - Reuters